Pressure BioSciences, Inc.
Technology Leader in a $26 Billion Market 
Company Reports 22% Increase in Revenue

Los Angeles - December 5, 2016 - StockWatchIndex (SWI) today is providing an update to its initial research report on  Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO).

Since the publication of SWI's first research report published in July 2016Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) has made significant progress towards achieving its goals, increased revenue by 22% over the last nine month period compared to 2015 and has received broad recognition in a large number of leading market publications. 

Click on logos to read the latest release 
Logos are the property of their respective owners
Pressure BioSciences' Patented Technology
Pressure BioSciences develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market, with a worldwide market estimated to be $26 Billion. PBIO's PCT technology is a patented technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, to safely and reproducibly control bio-molecular interactions in combination with widely used mass spectrometer systems by leading manufacturers, such as SCIEX.

Notable Recent Achievements 
PBIO has produced a number of notable achievements that we believe add critical strength and stability to the company and increase the acceptance and commercial traction of its PCT platform in both the scientific and investment communities worldwide. 
  • Generated total revenue surpassing half a million dollars for three consecutive quarters
  • Eliminated nearly $3 million in floor-less debt
  • Entered into co-marketing agreement with SCIEX, a leader in providing analytical instrumentation to the global life sciences field
  • Contracted new ISO-certified manufacturer and completed the build of four Barocycler 2320EXTREME instrument systems
  • Sold the first nine commercially-available units to customers in the US, Europe, Asia, and Australia
  • The Children's Medical Research Institute, the preeminent cancer research centers in Australia, in collaborate with the U.S. National Cancer Institute in President Obama's Cancer Moonshot initiative, purchased the first three commercially-available Barocycler 2320EXTREME instruments
PBI Pressure Cycling Technology - A Game Changer
Download the SWI Research Report Here
 S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been engaged by Small Cap Nation, an on-demand video news and information broadcasting platform and will be compensated in cash for the publication of the information herein . The included information is subject to change without notice. Please visit!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.